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Abstract
Severe asthma imposes a significant burden on patients, families and healthcare systems. 
Management is difficult, due to disease heterogeneity, comorbidities, complexity in care pathways 
and differences between national or regional healthcare systems. Better understanding of the 
mechanisms has enabled a stratified approach to the management of severe asthma, supporting 
the use of targeted treatments with biologicals. However, there are still many issues that require 
further clarification. These include selection of a certain biological (as they all target overlapping 
disease phenotypes), the definition of response, strategies to enhance the responder rate, the 
duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness. The 
EAACI Guidelines on the use of biologicals in severe asthma follow the GRADE approach in 
formulating recommendations for each biological and each outcome. In addition, a management 
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Abbreviations
ACQ = asthma control questionnaire 
AQLQ = asthma quality of life questionnaire
ACT = asthma control test 
AD = atopic dermatitis
ADA = anti-drug antibodies 
AR = allergic rhinitis
ATS = American Thoracic Society 
COI = conflict of interest
CRSwNP = chronic rhinosinusitis with nasal polyps
DCs = dendritic cells
EAACI = European Academy of Allergy and Clinical Immunology
ED = emergency department
EMA = European Medicines Agency
ERS = European Respiratory Society 
EtD = evidence-to-decision 
Fab = antigen-binding fragment 
Fc = fragment crystallizable
FcεRI = IgE high affinity receptor 
FDA = Food and Drug Administration
FeNO = fractional exhaled nitric oxide
FEV1 = Forced expiratory volume at the end of the first second of forced expiration
GDG = guidelines development group 
GETE = global evaluation of treatment effectiveness 
GINA = Global Initiative for Asthma 
GRADE = Grading of Recommendations Assessment, Development, and Evaluation 
HCP = healthcare professional
ICERs = incremental cost-effectiveness ratios 
ICS = inhaled corticosteroids
Ig = immunoglobulin
IL = interleukin
IL-4Rα = the α subunit of the IL-4 receptor 
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ISAR = International Severe Asthma Registry 
IV = intravenous
JAK = Janus kinase
Mab = monoclonal antibody
NICE = National Institute for Health and Care Excellence 
NK = natural killer
OCS = oral corticosteroids
PEF = peak expiratory flow 
PICO (population, intervention, comparator, and outcomes)
PI3K = phosphoinositide 3 kinase 
PROs = patient-reported outcomes 
QALY = quality adjusted life-years 
QoL = quality of life
ROB = risk of bias
SANI = Severe Asthma Network in Italy 
SMART = Standardized Measure to Assess Response to Therapy 
SMD = small molecule drug
SOF = summary of findings
SPACE = Severe Paediatric Asthma Collaborative in Europe
SRs = systematic literature reviews
STAT= signal transducer and activator of transcription
T2=type 2
TH = T helper
TNF = tumor necrosis factor
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I. Introduction
a. The current landscape of severe asthma
i. Definitions and burden
Asthma is a heterogeneous chronic inflammatory disease of the lower airways that affects nearly 
400 million people worldwide (1). It is the most frequent chronic disease in children. The current 
estimate is that 3 to 10% of adult asthmatics suffer from severe asthma (2). The real prevalence 
might be lower, as these figures include cases with poor adherence, untreated co-morbidities or 
misdiagnosis (3,4,5,6,7). Although severe asthma comprises a small proportion of asthma cases, 
it is associated with increased mortality and hospitalisation, reduced quality of life (QoL), and 
increased healthcare costs (8,9,10,11,12,13). Extrapolating adult severity classifications to 
children is difficult for a number of reasons ranging from the clinical phenotypes to lung function 
parameters and response to treatment. Therefore, the incidence of paediatric severe asthma 
affecting up to 2.5% of all children with asthma (15) is not directly comparable with the incidence 
of severe asthma in adults. In children, severe asthma accounts approximately for half of all 
healthcare resources for paediatric asthma and it is associated with increased risk of mortality, 
and of development of chronic obstructive pulmonary disease in adulthood (15,16,17,18,19).
The European Respiratory Society (ERS)/American Thoracic Society (ATS) guidelines set out a 
framework for the diagnosis and management of severe asthma in adults and children (20,21). 
The Global Initiative for Asthma (GINA) has produced a useful guide for the diagnosis and 
management of “Difficult-to-treat” and Severe Asthma in adolescents and adults (22). Patients 
with a confirmed diagnosis of asthma who have had modifiable factors addressed, poorly 
controlled while receiving high dose inhaled corticosteroid (ICS) treatment, or with requirement of 
a high level of treatment to maintain control are classified as severe asthma (20).
ii. Severe asthma phenotypes and endotypes - practical implications for 
management
Following recent advances in our understanding of asthma mechanisms and therapeutic 
responsiveness, the concept of asthma as a single entity has been replaced with a model of a 
complex biological network with distinct, but interrelating immune - inflammatory pathways 
continuously modified by multiple external and internal factors (23,24,25,26,27,28). Several 
visible properties underpin the definition of severe adult asthma phenotypes: clinical, functional, 
morphological, inflammatory, molecular and microbiome-related (25, 29, 30,31). However, severe 
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mechanisms; these are best described by disease endotypes. The major immune-inflammatory 
pathways for severe asthma include type-2 (T2) high, T2 low and mixed endotypes which may 
share certain genetic and epigenetic, metabolic, neurogenic and remodelling characteristics 
(24,31,32).
Severe paediatric asthma has been associated in most cases with severe and multiple 
aeroallergen sensitisation, allergic rhinitis, food allergy, eosinophilic airway inflammation, 
exposure to environmental tobacco smoke and airway remodelling (33, 34,35). Similar to adults it 
is quite heterogenous (36,37,38). Unfortunately, less is known about its endotypes and related 
biomarkers. Mechanisms of adult severe asthma cannot be extrapolated to children. Children 
with eosinophilic asthma may not have increases in other T2 markers (35). Unlike adults, 
intraepithelial neutrophils were associated with better lung function (39). The potential roles of the 
innate epithelial cytokine interleukin (IL)-33 and of lineage negative innate lymphoid cells (ILCs) 
are also described (40,41). 
The advent of biologicals for asthma represents a giant leap forward for severe asthma 
management. Considering the availability of several specific targeted therapies for T2 asthma, 
the management approach to severe asthma currently includes a phenotyping step for the 
identification of allergic and eosinophilic and non-T2 phenotypes (2, 20, 21,42). This stratified 
approach is based on measurement of biomarkers such as eosinophils in blood or sputum, 
fractional exhaled nitric oxide (FeNO) and specific immunoglobulin (Ig) E of clinical relevance 
(42,43,44,45,46). Whether this stratified approach will improve the burden of severe asthma 
remains to be proven by real-life studies and registry data (43,44,47). While targeted treatment 
strategies and mathematical models such as multidimensional endotyping are currently being 
tested, they will ultimately require validated guidelines for optimal implementation (30, 43, 48, 49, 
50). In addition, no specific investigation into tailored treatment for young children with severe 
asthma exists and the efficacy of biologicals is less frequently tested in children. The same holds 
true for treatment of T2-low severe asthma. Given the relatively high costs of biological therapies, 
cost-effectiveness analyses are a prerequisite for coverage and reimbursement. Carefully 
targeting biological therapy to specific populations, such as high-responders, or discounting the 
acquisition price in order to further improve value are currently advocated (51).
iii. Biologicals
Biologic products (biologicals) include a wide range of products such as vaccines, blood and 
blood components, allergenics, somatic cells, gene therapy, tissues, and recombinant therapeutic 
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and may be produced by biotechnology methods and other cutting-edge technologies. For the 
purpose of this guideline we refer to monoclonal antibodies (mAb) as biologicals.  In contrast to 
chemical compounds and small‐molecule agonists or antagonists, biologicals bind a specific 
determinant, for example, a cytokine or receptor. Owing to this selectivity, biologicals are ideal for 
‘personalized’ or ‘precision’ medicine (52).
iv. Current management of severe asthma
The GINA 2020 asthma guideline (2) recommends a decision tree for the diagnosis and 
management of severe asthma with distinct tasks for primary and specialised care while 
reinforcing the value of the patient perspective and collaborative care by primary care physicians, 
specialists and other healthcare professionals (HCP). At the specialist level, assessment of the 
severe asthma phenotype during high dose ICS treatment or lowest possible dose of oral 
corticosteroids (OCS) and of the factors contributing to symptoms, QoL and exacerbations are 
advocated. T2 inflammation is defined by the presence of blood eosinophils ≥150/μl and/or FeNO 
≥20 ppb and/or sputum eosinophils ≥2%, and/or asthma that is clinically allergen-driven and/or 
that require maintenance OCS. A tentative approach for first line biological targeting the T2 
pathway is based on biomarkers and predictors of response, while taking into consideration local 
payer eligibility criteria, cost, dosing frequency, route (subcutaneous or intravenous) and patient 
preference. Response to the biological is evaluated after 4 months and if favourable the biological 
is continued with re-evaluation every 3-6 months. If the patient fails to respond to the initial agent 
but is still eligible for T2 targeted treatment, GINA 2020 recommends switching to another 
biological. GINA 2020 acknowledges that at present there are no well-defined criteria for a good 
response, but recommends considering exacerbation frequency, symptom control, lung function, 
medication side-effects, treatment intensity (including OCS dose), and patient satisfaction as 
important factors.
The 2014 ERS/ ATS guidelines on severe asthma in adults and school age children introduced 
the definition of severe asthma as it is used today, and highlighted the necessity of always 
confirming the diagnosis of asthma and excluding other conditions that may mimic asthma. This 
guideline also provided specific recommendations for the use of sputum eosinophil count and 
FeNO to guide the phenotypic driven approach (20). The 2019 revision of the ERS/ATS 
guidelines provided some specific recommendations for the use of biologicals targeting the IL-5, 
IgE and IL-4/IL-13 pathways based on the Grading of Recommendations Assessment, 
Development, and Evaluation (GRADE) methodology (21). Recommendations are formulated for 
all anti IL-5 interventions together, receiving a conditional recommendation for use as add-on 
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adult patients with severe eosinophilic asthma, and for those with severe corticosteroid-
dependent asthma regardless of blood eosinophil levels. A blood eosinophil cut-point of ≥ 150/μl 
received a conditional recommendation to guide anti-IL-5 initiation in adult patients with severe 
asthma and specific eosinophil (≥ 260 /μl) and FeNO (≥19.5 ppb) cut-offs are suggested to 
identify adolescents or adults with the greatest likelihood or response to anti-IgE therapy.
Currently five biologicals are approved for severe asthma (in alphabetical order): benralizumab 
(53,54); dupilumab, (55,56); mepolizumab (57, 58); omalizumab, (59,60); and reslizumab,  
(61,62) (tables 1, 2 and 3).
b. Purpose of the EAACI Guidelines for the use of biologicals in severe asthma
Delivering high-quality clinical care is a central priority for allergists, pneumologists, paediatricians 
and other specialities caring for patients with allergic diseases and asthma. The European 
Academy of Allergy and Clinical Immunology (EAACI) develops and updates each year resources 
to help HCP and researchers to design the best interventions, deliver high standard care and to 
assess their actions and decisions for purposes of quality improvement and/or reporting. 
EAACI guidelines include recommendations for the management of patients with particular 
conditions or diseases. Guidelines are developed using a systematic process, and are based on 
available evidence and the clinical experience and expertise of all interested stakeholders.
EAACI developed a Position Paper on Biologicals in 2015 (52). Due to the rapid accrual of 
evidence and new therapies, advancement of guideline development methodologies, and the 
need to broaden the scope of the 2015 recommendations a new guideline was therefore needed.
The current guidelines address only treatment with biologicals of severe asthma and do not 
address any topics related to severe asthma correct diagnosis, background controller treatment, 
achieving asthma control, monitoring adherence or treating its co-morbidities. 
The EAACI Guidelines for the use of biologicals in severe asthma are not intended to impose a 
standard of care. Instead, they provide the framework for rational decisions for the use of 
biologicals in severe asthma by HCPs, patients, third-party payers, institutional review 
committees and other stakeholders. Statements regarding the underlying values and preferences 
as well as qualifying remarks accompanying each recommendation are an integral part of the 
Guidelines and aim to facilitate more accurate interpretation. They should never be omitted or 
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The target audience includes all HCPs involved in the management of severe asthma, patients 
and caregivers, basic scientists involved in biologicals development, regulatory authorities and 
policy makers.
ii. Biologicals included - rationale for choosing 
The EAACI guidelines provide recommendations for the use of biologicals with current regulatory 
approval in patients with severe asthma: benralizumab, dupilumab, mepolizumab, omalizumab, 
reslizumab (in alphabetical order).
Additional comments are provided for the biologicals currently tested and not yet approved and 
for doses/routes not approved by regulatory authorities.
II. Methods
The EAACI guidelines followed the GRADE methodology (available at 
www.gradeworkinggroup.org). Training was conducted with all members of the guidelines 
development group (GDG) to prepare them for their roles, including specific sessions on the 
GRADE methodology. 
a. The Guidelines Development Group
A Core Leadership Team (table S1) supervised the project and was responsible for defining the 
project scope, drafting the clinical questions to be addressed by the guideline, coordinating the 
search, and drafting the manuscript together with the Voting Panel (table S1). It was led by three 
chairs with both content and methodologic expertise. The Core Leadership Team received 
support from a methodologist team, who advised on the process and provide input on the 
GRADE summary of findings (SOF) tables and from experts in guideline development. 
The methodologist team conducted the systematic literature reviews (SRs) for each of the clinical 
questions, graded the quality of evidence, developed the SOF tables, and provided the evidence 
reports. Narrative reviews were conducted by different content specialist subgroups for each topic 
to be covered to complement the SRs.
The Voting Panel, composed of content experts, decided which clinical questions are to be asked 
and which outcomes are critical, important and of low importance, and voted for the final 
recommendations after reviewing the evidence provided by the methodology team and the 
narrative reviews. It included specialists with expertise and clinical experience in treating severe 
asthma, biologists and clinical immunology experts, as well as patient representatives.
In accordance with EAACI policy, everyone who was intellectually involved in the project (i.e., 
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the beginning, middle, and end of the project. The Guideline Oversight Committee (table S1) was 
responsible for developing and implementing rules related to COIs.
b. Definitions 
For the purpose of the three SRs (63,64,65) that informed the recommendations, severe asthma 
populations were defined as follows:
 Eosinophilic asthma: subjects with any of the following: a sputum eosinophil count of >1% 
or an asthma-related peripheral blood eosinophil count of ≥150 cells/ μL, or a fractional 
exhaled nitric oxide (FeNO) of ≥20 ppb (66)
 Allergic asthma: subjects diagnosed with moderate to severe allergic asthma with asthma 
symptoms due to exposure to a perennial aeroallergen and serum total IgE levels 30-
1300 IU/mL not adequately controlled on ICS and/or other background controllers.
 For dupilumab SR the severe T2 asthma population was defined as subjects with 
confirmed diagnosis of asthma inadequately controlled on ICS and additional controllers
For the recommendations the population was defined as in the clinical trials that informed the 
regulatory approval.
c. TF questions and prioritisations of key outcomes 
Clinically relevant interventions and comparators were developed balancing comprehensiveness 
with feasibility (table 4). The most challenging decision in framing the question was how broadly 
the patients and intervention should be defined. The underlying biology of asthma suggested that 
across the range of patients and interventions it is plausible that the magnitude of effect on the 
key outcomes is different, thus the GDG defined subpopulations based on age (6-11 years old, 
12-18 years old, > 18 years old), co-morbidities (chronic rhinosinusitis with nasal polyps 
(CRSwNP) for anti IL-5 interventions and dupilumab;  atopic dermatitis (AD) for dupilumab; 
chronic urticaria (CU), allergic rhinitis (AR) and food allergy for omalizumab, biomarkers (blood 
eosinophils, atopy, specific and total IgE, FeNO), dose, etc. The outcomes were evaluated per 
product and subgroup.
As required by the GRADE approach asthma-related outcomes were prioritised in a first step by 
the GDG using a 1 to 9 scale (7 to 9 critical; 4 to 6 important; 1 to 3 of limited importance). The 
critical outcomes were: severe asthma exacerbations, asthma control measured by the asthma 
control questionnaire (ACQ) and asthma control test (ACT), QoL measured by asthma quality of 
life questionnaire (AQLQ) and safety. The important outcomes were: lung function measured by 
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rescue medication use. FeNO, sputum and blood eosinophils were scored as low importance 
(table 5). After reviewing the evidence, the prioritisation of the outcomes was reassessed to 
ensure that important outcomes that were not initially considered are included and to reconsider 
the relative importance of outcomes in light of the available evidence. All asthma-related relevant 
outcomes were addresses simultaneously. As per GRADE methodology when surrogate 
outcomes were used (FeNO, FEV1) the quality of the evidence was down-graded.
The GDG framed a separate cost-effectiveness question to assess the economic impact of the 
biologicals versus standard of care. The outcomes of interest were costs and resources use, the 
incremental cost-effectiveness ratios (ICERs) per both quality adjusted life-years (QALY), and 
asthma-related outcomes.
The GDG also defined and addressed clinical questions not covered by the systematic reviews 
(table 6).
d. The minimal important difference
To evaluate the imprecision for each outcome the minimal important difference (MID) thresholds 
were considered: St George’s Respiratory Questionnaire (SGRQ) score change of 4 units, 
Asthma Control Questionnaire (ACQ-5, ACQ-6, and ACQ-7) score change of 0.5 units, Asthma 
Quality of Life Questionnaire (AQLQ) score change of 0.5 units (with disclaimer as calculated 
pre/post treatment), FEV1 change in litres 0.20, OCS reduction by 50% , rescue medication 
reduction by 0.81 puff/day and a reduction of at least 20% in FeNO for values over 50 ppb or 
more than 10 ppb for values lower than 50 ppb ( 67,68, 69,70). 
e. The GRADE approach (search, appraisal of the evidence)
Key principles and provisions, key terms, descriptions, drug categories, PICO (population, 
intervention, comparator, and outcomes) questions, search methodology and evidence reporting 
used in the guideline development process were predefined.
Separate systematic reviews on eosinophilic asthma (benralizumab, dupilumab, mepolizumab, 
omalizumab, reslizumab), allergic asthma (benralizumab, dupilumab, omalizumab) and severe T2 
asthma (dupilumab) were conducted to inform the recommendations (63,64,65). A GRADE SOF 
table was provided for each PICO question. The quality of evidence was evaluated based on 
GRADE quality assessment criteria by two independent reviewers and discordance resolved by 
consensus. Quality assessment includes the risk of bias (ROB) in included trials, the likelihood of 
publication bias, inconsistency between trial results, indirectness of the evidence (e.g., 
differences between populations, interventions, or outcomes of interest in the group to whom the 
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imprecision (wide confidence intervals, usually due to a small number of patients or events, or 
those situations where clinical decision-making would differ at the extremes of the confidence 
interval) (71,72). The quality of evidence for each outcome was rated as high, moderate, low, or 
very low. In the absence of any data, the level of evidence was rated as very low, based on 
clinical experience only. Search results were pooled in an evidence report as SOF tables and 
accompanied by a qualitative summary of the evidence for each PICO question.  The Content 
Panel reviewed the drafted evidence report to address evidence gaps prior to presentation to the 
Voting Panel.
f. Additional evidence 
In support of formulated recommendations, the GDG performed narrative reviews collecting 
evidence on phase IV, observational and real-world trials and on clinical questions not addressed 
by the SRs (table S2).
g. Consensus building and formulating recommendations
After reviewing the evidence report and the additional evidence, the Voting Panel decided in a 
face-to-face meeting followed by subsequent emails regarding the final recommendations. For 
each PICO question, the Voting Panel heard an oral summary of the evidence and provided 
votes on the direction and strength of the related recommendation. A 70% consensus threshold 
was reached for all recommendation presented below. The recommendations follow the data 
included in the evidence-to-decision (EtD) tables and take into consideration the balance of 
desirable and undesirable consequences, quality of evidence, patients’ values and preferences, 
feasibility, and acceptability of various interventions, use of resources paid for by third parties, 
equity considerations, impacts on those who care for patients, and public health impact (71,72). A 
strong recommendation was made in favour of an intervention when the GDG was certain that 
the desirable consequences outweighed the undesirable consequences. A conditional 
recommendation was provided if there were reasons for uncertainty on the benefit-risk profile, 
especially for low or very low quality of evidence. The underlying values and preferences played 
a key role in formulating recommendations. As the key target audience of the EAACI Guidelines 
are HCPs and the patients they treat, the perspective chosen when formulating recommendation 
was mainly that of the HCPs and of the patient, although the health systems perspective was also 
evaluated (73). Recommendation are provided per product, per subgroups and per outcomes. 
The recommendations formulated in these guidelines should be used following the GRADE 
interpretation (table 7). These recommendations should be reconsidered when new evidence 
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Where no evidence was available the GDG formulated expert-based recommendations.
The Guidelines were available on the EAACI website for two weeks (20 April- 4 May) for public 
comment and were external peer-reviewed. All comments received were carefully revised by the 
GDG and where applicable incorporated.
h. Final review and approval of the guideline by EAACI
In addition to journal and external peer review, the EAACI Scientific Committee and Executive 
Committee reviewed the manuscript. These EAACI over-sight groups did not mandate that 
certain recommendations be made within the guideline, but rather serve as peer reviewers.
III. Key recommendations (biologicals are mentioned in alphabetical order)
III.A.  Benralizumab – severe eosinophilic asthma – adults and paediatric population 12-17 years 
old
IL-5 is one of the major cytokines responsible for the growth, differentiation, recruitment, 
activation and survival of eosinophils. Benralizumab is a humanised Mab that binds to the α 
subunit of the IL-5 receptor (IL-5Rα) via its antigen-binding fragment (Fab) domain, blocking the 
binding of IL-5 to its receptor and resulting in inhibition of eosinophil differentiation and maturation 
in bone marrow. In addition, this antibody is able to bind through its afucosylated fragment 
crystallizable (Fc) domain of the IgG receptor FcyRIIIa on natural killer (NK) cells, macrophages, 
and neutrophils, thus strongly inducing antibody-dependent, cell-mediated cytotoxicity in both 
circulating and tissue-resident eosinophils (74). This double function of benralizumab rapidly 
induces and maintains depletion of eosinophils that is much greater than that induced by other 
monoclonal antibodies targeting the IL-5 pathway (75,76). This effect translates clinically into a 
rapid and significant improvement of patient reported outcomes (PROs) and of lung function 
(peak expiratory flow (PEF), together with a significant decrease in asthma exacerbations and 
OCS use (77,78,79, 80, 81).
The summary of the supportive evidence is presented in tables S3 and S4. Recommendations 
are based on the evidence-to-decision tables S5,S6,S7.
Recommendations are formulated separately for the adult population (Box 1) and the 12-17 years 
old population (Box 2)
Box 1: Recommendations for benralizumab as add-on treatment in adults with 
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Decrease or withdraw oral 




Improve quality of life Conditional 
recommendation
Improve asthma control Conditional 
recommendation






asthma* in spite of 
optimal controller 
treatment to:
Improve lung function Conditional 
recommendation**
2. Benralizumab demonstrated a good safety profile however 
patients should be regularly screened for parasitic infections 
in endemic areas 
Conditional 
recommendation
* population: severe asthma uncontrolled by high-dosage ICS +LABA with baseline blood 
eosinophil cell counts > 300 cells/μL or >150 cells/μL for OCS-dependent patients
** although the effect size is small it might be beneficial in patients with very low lung function
Box 2: Recommendations for benralizumab as add-on treatment in the paediatric 
population 12-17 years old with uncontrolled severe eosinophilic asthma




Improve quality of life Conditional 
recommendation
Improve asthma control Conditional 
recommendation
1. Benralizumab is 
recommended in in 
the paediatric 
population 12-17 
years old with 
uncontrolled 
severe eosinophilic 
asthma* in spite of 
optimal controller 
treatment to:
Improve lung function Conditional 
recommendation**
2. Benralizumab demonstrated a good safety profile however 
patients should be regularly screened for parasitic infections 
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* population: severe asthma uncontrolled by high-dosage ICS +LABA with baseline blood 
eosinophil cell counts > 300 cells/μL or >150 cells/μL for OCS-dependent patients
** although the effect size is small it might be beneficial in patients with very low lung function
Justification
There is high certainty for adults for decreasing asthma exacerbations in the overall group and for 
OCS decrease in the subgroup with > 150 eosinophils/ μL. Although there is high certainty for 
improving asthma control and QoL the effect of benralizumab did not reach the MID, thus a 
conditional recommendation was formulated.
The GDG formulated conditional recommendations for the paediatric population due to the low 
numbers of subjects 12-17 years old included in clinical trials.
Subgroups: stratified by biomarkers and co-morbidities
The higher the blood eosinophils the higher the expected impact of benralizumab on 
exacerbations, asthma control, QoL and lung function (table S8) (conditional recommendation)
Neither the atopic status or total IgE predict the magnitude of effect of benralizumab (conditional 
recommendation) (table S9)  
Benralizumab can be recommended in patients with severe eosinophilic asthma and CRSwNP 
uncontrolled despite optimal treatment to:
1. Decrease asthma exacerbations (conditional recommendation)
2. Improve lung function (conditional recommendation) (table S10)
III.B. Benralizumab – severe allergic asthma - adults
In humans, IL‐5 is often co‐expressed with other T2 cytokines including IL‐4 and IL‐13 and 
associated in atopic individuals with increased IgE production (28, 30, 31, 82, 83). Thus, targeting 
the IL-5 pathway might be beneficial in allergic asthma.
From all anti IL-5 biologicals only benralizumab was evaluated in the regulatory approved dose in 
a post-hoc analysis of a subpopulation of adults with severe allergic asthma (84). 
The summary of the supportive evidence is presented in tables S11 and S12. Recommendations 
are based on the evidence-to-decision tables S13, S14, S15 and are presented in box 3
Box 3: Recommendations for benralizumab as add-on treatment in adults with 
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Improve quality of life Conditional 
recommendation
Improve asthma control Conditional 
recommendation





asthma* in spite of 
optimal controller 
treatment to:
Improve lung function Conditional 
recommendation**
2. Benralizumab demonstrated a good safety profile however 
patients should be regularly screened for parasitic infections 
in endemic areas 
Conditional 
recommendation
* population: severe asthma uncontrolled by high-dosage ICS +LABA with baseline blood 
eosinophil Cell counts >300 cells/μL or > 150 cells/μL meeting the criteria for atopy (by 
Phadiatrop test) and serum IgE concentration of 30 to 700 kU/L (US) and 30 to 1500 kU/L (EU)
** although the effect size is small it might be beneficial in patients with very low lung function
Justification
There is high certainty for adults for decreasing asthma exacerbations, however, data are derived 
from a post-hoc analysis. Although there is high certainty for improving asthma control and QoL 
the effect of benralizumab did not reach the MID, thus a conditional recommendation was 
formulated.
III.C. Dupilumab – severe eosinophilic asthma - adults and paediatric population 12-17 years old
IL-4 and IL-13 are key cytokines in driving the initiation and the chronicity of T2 inflammation, 
where IL-4 is considered an initiator of T2 immune responses and IL-13 an effector molecule (85 
86, 87,88,89). Dupilumab is a human IgG4 Mab that targets the IL-4 receptor alpha chain (IL-
4Rα), common to both IL-4R complexes: type 1 (IL-4Rα/γc; IL-4 specific) and type 2 (IL-4Rα/IL-
13Rα1; IL-4 and IL-13 specific) (90,91). In mice models dual IL-4/IL-13 blockade prevents 
eosinophil infiltration into lung tissue without affecting circulating eosinophils (90). Supported by a 
strategic mechanism of action inhibiting T2 mediated inflammation dupilumab’s efficacy has been 
assessed across a range of atopic diseases, such as AD, asthma, and chronic rhinosinusitis with 
nasal polyps (CRSwNP) which often occur together as co-morbidities (91). Previous to being 
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dermatitis (AD) and CRSwNP and in Europe for AD. Convincing clinical results were recently 
published for severe uncontrolled asthma (92,93,94) and for CRSwNP (95).
The summary of the supportive evidence is presented in tables S16 and S17. Recommendations 
follow the evidence-to-decision tables S18 and S19.
Recommendations are formulated for the adult and adolescent population altogether (Box 4) as 
we did not perform a separate analysis for the 12-17 years old subgroup
Box 4: Recommendations for dupilumab as add-on treatment in adults and paediatric 
population 12-17 years old with uncontrolled severe eosinophilic asthma




Improve quality of life Conditional 
recommendation
Improve asthma control Conditional 
recommendation
Improve lung function** Strong 
recommendation









asthma* in spite of 
optimal controller 
treatment to:
Decrease rescue medication use*** Conditional 
recommendation
2. Dupilumab demonstrated a good safety profile, however 
longer-term data (up to 2 years) are extrapolated from atopic 
dermatitis studies and careful reporting of all drug-related 
adverse events is recommended
Conditional 
recommendation
* population: severe asthma uncontrolled by medium/high-dose ICS plus up to 2 additional 
controllers including OCS; T2 inflammation (EMA requirements) characterised by raised blood 
eosinophils (> 150) and/or raised FeNO >20 
** population: adult subgroup with blood eosinophils > 300 cells/μL or with FeNO levels > 50 ppb 
(64)
*** although the effect size is small it might be beneficial in patients with increased risk due due to 
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There is high certainty for adults for decreasing asthma exacerbations and moderate certainty for 
improving asthma control and QoL and the decrease in rescue medication use, thus a conditional 
recommendation was formulated. The increase in FEV1 is significant (above the MID) for the 
adult subgroup with blood eosinophils > 300 cells/μL or with FeNO levels > 50 ppb (64). More 
efficacy and safety data are needed in the paediatric population. 
Subgroups: stratified by biomarkers and co-morbidities
The higher the blood eosinophils and FeNO the higher the clinical efficacy of dupilumab, both in 
reduced exacerbations and in improving lung function (conditional recommendation) (tables S20 
and S21).
Dupilumab can be recommended in adults and adolescents with severe eosinophilic asthma with 
chronic rhinosinusitis with nasal polyps who are uncontrolled despite optimal treatment to:
1. Decrease exacerbations (conditional recommendation)
2. Improve asthma control (conditional recommendation)
3. Improve quality of life (conditional recommendation)
4. Improve lung function (conditional recommendation)
III.D. Dupilumab –severe allergic asthma – adults and paediatric population 12-17 years old
Ligand binding of the type 1 (IL-4Rα/γc; IL-4 specific) and type 2 (IL-4Rα/IL-13Rα1; IL-4 and IL-
13 specific) receptors activates a signal transduction cascade that mainly leads to the modulation 
of expression of genes involved in IgE class switching, T helper (TH) 2 cell differentiation, and M2 
macrophage polarization (31, 82, 86, 87, 88). IL-4 has been shown to stimulate IgE production 
from B cells. In asthma, IL-4 plays a major role in TH2 cell proliferation, cytokine production, and 
IgE synthesis. Combined analyses of genetic alterations in the IL-4/IL-13 pathway showed a 
profound influence on serum IgE levels and the risk of childhood asthma (96). Dupilumab was 
specifically evaluated in a post-hoc analysis of patients with moderate to severe allergic asthma 
enrolled in QUEST trial. Allergic asthma was defined by total serum IgE ≥30 IU/mL and ≥1 
perennial aeroallergen-specific IgE ≥0.35 kU/L at baseline (97).
The summary of the supportive evidence is presented in tables S22 and S23. Recommendations 
follow the evidence-to-decision tables S24 and S25. 
Recommendations are formulated for the adult and adolescent population altogether (Box 5) as 
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Box 5: Recommendations for dupilumab as add-on treatment in adults and in the 
paediatric population 12-17 years old with uncontrolled severe allergic asthma




Improve asthma control Conditional 
recommendation
1. Dupilumab is 
recommended in 
adults and in the 
paediatric 
population 12-17 
years old with 
uncontrolled 
severe allergic 
asthma* in spite of 
optimal controller 
treatment to:
Improve lung function** Conditional 
recommendation
2. Dupilumab demonstrated a good safety profile, however 
longer term data (up to 2 years) are extrapolated from atopic 
dermatitis studies and careful reporting of all drug-related 
adverse events is recommended
Conditional 
recommendation
* population: severe asthma uncontrolled by medium/high-dose ICS plus up to 2 additional 
controllers including OCS; T2 inflammation (EMA requirements) characterised by raised blood 
eosinophils (> 150) and/or raised FeNO >20 
** population: adults subgroup with blood eosinophils > 300 cells/μL or with FeNO levels > 50 ppb 
(64) 
Justification
There is high certainty for adults for decreasing asthma exacerbations and for improving asthma 
control. However, because the improvement in asthma control did not reach the MID a 
conditional recommendation was formulated. The increase in FEV1 is significant (above the MID) 
for the adults subgroup with blood eosinophils > 300 cells/μL or with FeNO levels > 50 ppb (64). 
More efficacy and safety data are needed in the paediatric population. As data are derived from a 
post-hoc analysis a conditional recommendation was formulated.
III.E. Dupilumab –severe T2 asthma – adults and paediatric population 12-17 years old
T2 asthma encompasses several pathways that are concomitantly activated, including cells of the 
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cells which are effective producers of a variety of cytokines and seem to play important roles in 
the development of non-allergic asthma (27,30,32). IL-13 cytokine serum levels were significantly 
high in atopic and non-atopic asthma patients compared to healthy controls. IL-4 and IL-13 can 
curtail chemotaxis and several effector functions of neutrophils in humans (98,99). In a recent 
analysis of the QUEST trial dupilumab reduced severe exacerbation rates, improved FEV1 and 
asthma control, and suppressed T2 inflammatory biomarkers in patients with uncontrolled, 
moderate-to-severe asthma with or without evidence of allergic asthma (97). Following this 
rationale, the GDG decided to perform a SR on the efficacy and safety of dupilumab without 
using the criteria for eosinophilic or allergic asthma (65). This SR is the basis for the 
recommendations for dupilumab as add-on treatment in patients with T2 asthma uncontrolled 
under medium to high dose ICS plus up to two additional controllers.
The summary of the supportive evidence is presented in tables S26 and S27. Recommendations 
follow the evidence-to-decision tables S28, S29, S30. 
Recommendations are formulated for the adult and adolescent population altogether (Box 6) as 
there were no differences between the adults and the 12-17 years old subgroup
Box 6: Recommendations for dupilumab as add-on treatment in adults and paediatric 
population 12-17 years old with uncontrolled severe T2 asthma








Improve quality of life Conditional 
recommendation
Improve asthma control  Conditional 
recommendation
Improve lung function*** Strong  
recommendation





years old with 
uncontrolled 
severe T2 asthma* 
in spite of optimal 
controller 
treatment to: Decrease rescue medication**** Conditional 
recommendation
2. Dupilumab demonstrated a good safety profile, however 
longer term data (up to 2 years) are extrapolated from atopic 
dermatitis studies and careful reporting of all drug-related 
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* population: severe asthma uncontrolled by medium/high-dose ICS plus up to 2 additional 
controllers including OCS; T2 inflammation (EMA requirements) characterised by raised blood 
eosinophils (> 150) and/or raised FeNO >20 
**population: Patients with severe asthma on maintenance OCS and high dose ICS in 
combination with a second controller
***population: adult subgroup with blood eosinophils > 300 cells/μL or with FeNO levels > 50 ppb 
(65) or OCS dependent patients (94)
**** although the effect size is small it might be beneficial in patients with increased risk due to 
excessive use of rescue medication
Justification
There is high certainty for adults for decreasing asthma exacerbations and for OCS reduction.  
Although there is high certainty for improving asthma control and QoL the effect does not reach 
above the MID, thus a conditional recommendation was formulated. The increase in FEV1 is 
significant (above the MID) for the adult subgroup with blood eosinophils > 300 cells/μL and/or 
with FeNO levels > 50 ppb (65) and for OCS dependent patients (94). More efficacy and safety 
data are needed in the paediatric population. 
Subgroups:
Dupilumab is effective both in allergic* and nonallergic asthma in a T2 asthma context 
(conditional recommendation) 
*a total serum IgE ≥30 IU/mL and ≥1 positive perennial aeroallergen-specific IgE value (≥0.35 
kU/L) at baseline (table S31 A and B)
III.F. Mepolizumab – eosinophilic severe asthma – adults and paediatric population 12-17 years 
old
Mepolizumab is humanised Mab of IgG1 κ type, which targets human IL-5 with high affinity and 
specificity. Mepolizumab inhibits the bioactivity of IL-5 with nanomolar potency by blocking the 
binding of IL-5 to the alpha chain of the IL-5 receptor complex expressed on the eosinophil cell 
surface, thereby inhibiting IL-5 signalling and reducing the production and survival of eosinophils 
(100). It was approved for severe asthma with peripheral eosinophilia. Good control of peripheral 
eosinophilia has been readily demonstrated together with translation into a significant reduction in 
asthma exacerbations and an OCS sparing effect (101,102,103). Its effect on asthma control, 
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The summary of the supportive evidence is presented in tables S32 and S33. Recommendations 
follow the evidence-to-decision tables S34, S35, S36, S37.
Recommendations are formulated separate for the adult population (Box 7) and the 12-17 years 
old population (Box 8)
Box 7: Recommendations for mepolizumab as add-on treatment in adults with 
uncontrolled severe eosinophilic asthma








Improve quality of life Conditional 
recommendation
Improve asthma control Conditional 
recommendation





asthma* in spite of 
optimal controller 
treatment to:
Improve lung function Conditional 
recommendation**
2. No recommendation can be made for reducing rescue medication use as the effect 
size is small
3. Mepolizumab demonstrated a good safety profile (long term 
safety data up to 5 years), however patients should be 
regularly screened for parasitic infections in endemic areas 
Conditional 
recommendation
* population: Severe eosinophilic asthma defined as presence of eosinophilic inflammation 
determined by a blood eosinophil level of either 300 cells or more per μL in the past 12 months or 
150 cells or more per μL at initiation. 
** although the effect size is small the improvement might be relevant in severe asthma with very 
low lung function
Box 8: Recommendations for mepolizumab as add-on treatment in paediatric population 
12-17 years old with uncontrolled severe eosinophilic asthma




1. Mepolizumab is 
recommended in 
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corticosteroids recommendation
Improve quality of life Conditional 
recommendation




asthma* in spite of 
optimal controller 
treatment to:
Improve lung function Conditional 
recommendation
2. Mepolizumab demonstrated a good safety profile (long term 
safety data up to 5 years), however patients should be 
regularly screened for parasitic infections in endemic areas 
Conditional 
recommendation
* population: Severe eosinophilic asthma defined as presence of eosinophilic inflammation 
determined by a blood eosinophil level of either 300 cells or more per μL in the past 12 months or 
150 cells or more per μL at initiation. 
No recommendations can be formulated for children 6 -11 years old as per extrapolated data 
from mepolizumab 12-17 population.
Justification
There is high certainty for the decrease of moderate and severe asthma exacerbations and for 
the decrease in OCS and moderate or low certainty for improving asthma control, quality of life 
and lung function and for monitoring for parasitic infections. Only conditional recommendations 
can be formulated for the paediatric group 12-17 years old as there were low numbers enrolled in 
clinical trials.
Subgroups: stratified by biomarkers and co-morbidities
The higher the blood eosinophils the higher the expected impact of mepolizumab on 
exacerbations (table S38) (conditional recommendation).
Mepolizumab can be recommended in adult patients with severe eosinophilic asthma and 
CRSwNP uncontrolled despite optimal treatment to:
 decrease asthma exacerbations (conditional recommendation)
 decrease or withdraw OCS (conditional recommendation)
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 Improve quality of life (conditional recommendation)
For the use of mepolizumab in allergic asthma in a licensed dose an open multicenter, open-
label, single-arm study showed clinically significant improvements in asthma control, health 
status, and exacerbation rate (104). The post hoc meta-analysis of two phase 3 studies showed 
efficacy of mepolizumab regardless of allergic characteristics or omalizumab eligibility (105).  
Recent reports show that both mepolizumab and reslizumab can control severe asthma patients 
that failed to respond to omalizumab (106). The GDG considered that there are not enough data 
to conduct a SR on the licenced dose of mepolizumab in severe allergic asthma and a 
recommendation cannot be currently formulated. 
III.G. Omalizumab – severe eosinophilic asthma - adults 
While immunoglobulin E is a prominent biomarker for early-onset asthma, its serum levels is 
often also elevated in non-allergic late-onset asthma. The pattern of IgE expression in the latter is 
mostly polyclonal and frequently associated with high blood eosinophils (107, 108). The innate 
immune response also significantly contributes to this asthma phenotype. Release of IL-33 and 
TSLP from respiratory epithelium and activation of ILC2s via its receptor ST2 followed by T2 
cytokine release from ILC2s and TH 2 cells drives further massive local B-cell activation and IgE 
formation, mast cell degranulation, and finally eosinophil attraction (99, 109, 110). Omalizumab 
indirectly downregulates the IgE high affinity receptor (FcεRI) expression on basophils, mast 
cells, and dendritic cells (DCs), decreasing T2 cytokine production and inhibiting the eosinophilic 
inflammation (111,112,113,114,115,116,117). Through a different mechanism, long-term 
omalizumab treatment dampens T2 inflammation acting on different cell types that play a pivotal 
role in the pathogenesis of asthma such as plasmacytoid DCs (pDCs) and CD-4 T helper cells 
(118).  Several publications of case reports or short series describe the use of omalizumab adults 
and children suffering from severe non‐allergic asthma, sometimes reporting the successful 
withdrawal of systemic corticosteroids under treatment (119,120,121). Better response to 
omalizumab for eosinophil counts >300 cells/μL were shown in a prospective trial and in a recent 
pooled analysis of the two pivotal trials of omalizumab in allergic asthma (122,123,124). 
However, in two real life studies omalizumab proved its efficacy regardless of the blood 
eosinophils status (125,126).
The summary of the supportive evidence is presented in table S39. Recommendations follow the 
evidence-to-decision tables S40, S41. Recommendations are formulated only for the adult 
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Box 9: Recommendations for omalizumab as add-on treatment in adults with uncontrolled 
severe eosinophilic asthma (both allergic and non-allergic)




Improve quality of life Conditional 
recommendation
Improve lung function Conditional 
recommendation**





asthma* in spite of 
optimal controller 
treatment to:
Decrease the use of rescue medication Conditional 
recommendation***
2. Omalizumab has demonstrated a long-term (> 10 years) 
good safety profile, however 60 minutes monitoring for 




* population: adults with uncontrolled severe persistent allergic asthma with FENO ≥24ppb, and 
blood eosinophil counts ≥260/µl
** although the effect size is small the improvement might be relevant in severe asthma with very 
low lung function
*** although the effect size is small it might be beneficial in patients with increased risk due to 
excessive use of rescue medication
**** the recommendations on the duration of monitoring after omalizumab injection and for the 
first 3 administrations are expert opinion-based following the data reported in the literature (127); 
of note anaphylaxis has also been documented two hours after administration and beyond 1 year 
after beginning regularly administered treatment, thus it is up to the clinician to decide based on 
the personal history of the patient 
III.H. Omalizumab – moderate to severe allergic asthma – adults and paediatric population 12-17 
years old
The first in a new class of biological therapies for allergic asthma, omalizumab works by binding 
to free IgE thereby, reducing the amount available to bind the IgE high affinity receptor (FcεRI) on 
mast cells, basophils and antigen presenting cells (80). The ability to detach IgE from its receptor 
following omalizumab was recently described (128). The pDCs act at the crossroads between 
innate and adaptive immunity. IgE receptor cross-linking on pDCs suppresses their anti-viral 
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circulating IgE might generally strengthen anti-viral immune responses following omalizumab 
administration (129,130). Pre-clinical and clinical evidence supports the existence of a close 
counter-regulation of the high-affinity IgE receptor and interferon (IFN) pathways, and a potential 
dual mechanism of action and therapeutic benefit for omalizumab, which may enhance the 
prevention and treatment of virally induced asthma exacerbations (131,132,133,134). Extensive 
experience with omalizumab treatment for severe allergic asthma confirmed its effectiveness and 
safety, reducing symptoms, frequency of reliever use, and severe exacerbations (135,136, 
137,138,139,140,141).
The summary of the supportive evidence is presented in tables S42 and S43.  Recommendations 
follow the evidence-to-decision tables S44 and S45. As we did not perform a separate analysis 
for the 12-17 population recommendations are formulated altogether for the adult and adolescent 
(12-17 years old) population (Box 10) 
Box 10: Recommendations for omalizumab as add-on treatment in adults and the 
paediatric population 12-17 years old with uncontrolled moderate-to-severe allergic 
asthma




Improve asthma control Conditional 
recommendation
Improve quality of life Conditional 
recommendation
Decrease in the use of ICS Conditional 
recommendation**
1. Omalizumab is 
recommended in 
adults and the 
paediatric 
population 12-17 
years old with 
uncontrolled 
severe allergic 
asthma* in spite of 
optimal controller 
treatment to:
Decrease the use of rescue medication Conditional 
recommendation***
2. Omalizumab has demonstrated a long-term (> 10 years) 
good safety profile, however 60 minutes monitoring for 




* population: Moderate-to-severe asthma, total IgE level of 30–700 IU/ml (US) and 30 -1500 IU/ml 
(EU)  ± one perennial aeroallergen
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*** although the effect size is small it might be beneficial in patients with increased risk due to 
excessive use of rescue medication
**** the recommendations on the duration of monitoring after omalizumab injection and for the 
first 3 administrations are expert opinion-based (127); of note anaphylaxis has also been 
documented two hours after administration and beyond 1 year after beginning regularly 
administered treatment, thus it is up to the clinician to decide based on the personal history of the 
patient 
Justification
There is high certainty for the decrease in asthma exacerbations. Although there is high certainty 
for improving quality of life and for decreasing ICS and rescue medication use the GDG 
formulated conditional recommendations as the effect size did not reach the MID (where 
applicable) or was very small or there was a large confidence interval. There was moderate 
certainty for improving asthma control, not reaching the MID, however there was high certainty for 
the improvement in the global evaluation of treatment effectiveness (GETE).
Subgroups: stratified by biomarkers and co-morbidities
Serum IgE thresholds (within regulatory limits) do not influence response (conditional 
recommendation)
The effect of omalizumab on exacerbations does not depend on blood eosinophils (conditional 
recommendation) (table S46).
Omalizumab may control associated co-morbidities such as allergic rhinitis, chronic urticaria food 
allergy, CRSwNP but asthma-related recommendations and posology should be primarily used 
(conditional recommendation, expert opinion based).
III.I. Omalizumab  – moderate to severe allergic asthma – paediatric population 6 -11 years old
As there is good evidence with omalizumab for the paediatric asthma subgroup 6-11 years old a 
separate analysis was performed (see evidence to decision table S47) and the GDG formulated 
separate recommendations (box 11). 
Box 11: Recommendations for omalizumab as add-on treatment for children 6-11 years old 
with uncontrolled moderate-to-severe allergic asthma
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exacerbations recommendation
Improve asthma control Conditional 
recommendation
Improve quality of life Conditional 
recommendation
recommended for 
children 6-11 years 
old with 
uncontrolled 
allergic asthma* in 
spite of optimal 
controller 
treatment to:
Decrease in the use of ICS Conditional 
recommendation**
2. Omalizumab has demonstrated a long-term (> 10 years) 
good safety profile, however 60 minutes monitoring for 
anaphylaxis is recommended for the first 3 administrations***
Conditional 
recommendation








* population: Moderate-to-severe asthma, total IgE level of 30–700 IU/ml (US) 30–1500 IU/ml 
(EU) ± one perennial aeroallergen
**of particular importance for the paediatric population
*** the recommendations on the duration of monitoring after omalizumab injection and for the first 
3 administrations are expert opinion-based (127); of note anaphylaxis has also been documented 
two hours after administration and beyond 1 year after beginning regularly administered 
treatment, thus it is up to the clinician to decide based on the personal history of the patient 
III.J. Reslizumab  – severe eosinophilic asthma - adults
Reslizumab is an IL-5 antagonist (IgG4-kappa) binding to the IL-5 using a different epitope as 
compared to mepolizumab and in vitro with greater potency (142). It is administered via 
intravenous (iv) infusion and dosing is based on patients’ weight (143). Administration is 
recommended immediately after preparation. In clinical trials, rare cases of anaphylaxis were 
observed within 20 minutes of infusion and was reported as early as the second dose.  The 
pooled analysis of six clinical trials reports only three cases of anaphylaxis related to reslizumab, 
successfully managed with standard therapies (144). By week 52 patients receiving reslizumab 
showed a 92% reduction in mean blood eosinophil counts, and this effect translates into a 
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The summary of the supportive evidence is presented in tables S48 and S49. Recommendations 
(box 12) follow the evidence-to-decision tables S50, S51 and S52. 
Box 12: Recommendations for reslizumab as add-on treatment in adults with uncontrolled 
severe eosinophilic asthma




Improve quality of life Conditional
Recommendation
Improve asthma control Conditional 
recommendation





asthma* in spite of 
optimal controller 
treatment to:
Improve lung function Conditional 
recommendation**
2. No recommendation can be made for reducing rescue medication use as the effect 
size is small; OCS reduction is not reported
3. Reslizumab demonstrated a good safety profile however:
a.  patients should be regularly screened for parasitic 
infections in endemic areas 
b. patients should be carefully monitored 30 minutes  
after the iv administration for the risk of anaphylaxis 
Conditional 
recommendation
* population: at least one blood eosinophil count of 400 cells per μL or higher during a 2–4 weeks 
screening period and inadequately controlled asthma, receiving at least a medium dose of ICS 
with or without another controller drug including OCS
** although the effect size is small the improvement might be relevant in severe asthma with very 
low lung function
Justification: Although there is high certainty for improving asthma control and QoL the effect 
does not reach the minimal important difference; thus, a conditional recommendation was 
formulated. There is moderate certainty for improving lung function and low certainty for 
monitoring for parasitic infections and the iv administration.
Subgroups: stratified by biomarkers and co-morbidities
The higher the blood eosinophils the higher the expected impact of reslizumab on lung function 
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Reslizumab can be recommended in patients with severe eosinophilic asthma with CRSwNP 
uncontrolled despite optimal treatment to:
1. decrease moderate and severe asthma exacerbations (conditional recommendation)
2. Improve asthma control (conditional recommendation) (table S54)
Additional considerations: Reslizumab’s flexibility in dosage based on body weight might 
benefit patients with uncontrolled severe eosinophilic asthma not responding to other anti IL-5 
interventions (conditional recommendation, expert opinion based)
As there are no paediatric data available no recommendations can be formulated for the use of 
reslizumab in children with uncontrolled severe asthma.
III.K. Comparison between biologicals
No comparison can be made between the efficacy and safety of different biologics (strong 
recommendation, expert opinion based). Baseline asthma severity, atopic status definition, lung 
function, eosinophil cut-offs or exacerbation history and asthma duration are all important 
modulators of treatment efficacy. The rate of background exacerbations (in year prior to trial) or 
the placebo exacerbations rate (during the trial) should also be considered. These differ across 
trials because of different inclusion or exclusion criteria, thus the indirect treatment comparisons 
may be erroneous or biased.
III.L. Implementation consideration (for all biologicals)
The GDG formulated strong recommendations for the reduction in asthma exacerbations and for 
the reduction in OCS dose and conditional recommendations for the other asthma-related 
outcomes. According to GRADE for strong recommendations most individuals should receive the 
intervention and the recommendation can be adapted as policy or performance measure in most 
situations (table 6). However, the GDG cautions on several unsolved key pillars supporting the 
implementation of these recommendations, such as independent high-quality cost-effectiveness 
studies, selection of responders, documentation of the disease modifying effect together with 
long-term safety data, studies addressing a priori severe asthma together with its co-morbidities. 
Additional considerations are acceptability of the iv administration for reslizumab or the possibility 
of self-administration of biologicals at home and at longer intervals (149). The cost-effectiveness 
of biologicals based on real-world treatment patterns is unknown. Including broader evidence on 
treatment discontinuation, caregiver burden, and OCS reduction from real-world studies and 
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stakeholders (48). Last but not least the value of the recommendations depends also on the 
setting in which the current guideline will be implemented, as recommendation suitable for 
resource-rich environments might change from strong to conditional in resource-poor 
environments.
IV. Other biologicals currently tested for severe asthma
Thymic stromal lymphopoietin (TSLP) is a critical upstream epithelial derived cytokine inducing 
T2 inflammation. TSLP activates distinct immune cell cascades in the context of innate and 
adaptive immune-mediated T2 inflammation (150). TSLP’s importance in human asthma has 
been repeatedly documented (151,152,153). Targeting of TSLP-mediated signalling is a potential 
therapeutic strategy for severe asthma.
Tezepelumab, which is the first-in-class anti-TSLP mAb, is a fully human IgG2λ mAb that binds 
human TSLP and prevents interaction with its receptor. Because of the excellent results in the 
phase II trial which showed a notable reduction in the annual asthma exacerbation rate in a large 
population of severe asthma patients (154), FDA granted tezepelumab a 'breakthrough therapy 
designation' for the treatment of severe asthma without an eosinophilic phenotype (155). The 
drug is currently in Phase III clinical trials. In order to formulate a preliminary opinion a SR was 
performed for tezepelumab following the same methodology as for the currently approved 
biologicals for asthma (table S55). There was moderate certainty that tezepelumab decreases 
asthma exacerbations, low certainty for improving asthma control and QoL and very low certainty 
for improving FEV1 and for decreasing FeNO. There was low certainty for an increase in 
treatment related AEs and SAEs. The subgroup analysis by eosinophil and FeNO levels found no 
difference for the exacerbation rate and FEV1. For FEV1 another subgroup analysis by IgE levels 
found no difference either. 
MSTT1041A, an anti-ST2 (IgG2) human monoclonal antibody has recently been tested in a 
phase IIb trial and results are soon to be published (151). Several other anti IL-33 Mabs are 
currently being tested (156). The anti-IL-33 antibody REGN3500 (SAR440340) met the primary 
endpoint of improvement in loss of asthma control when comparing REGN3500 monotherapy to 
placebo. The greatest improvement was observed in patients with blood eosinophil levels ≥300 
cells/microliter (157). Other anti-IL-33 antibodies, GSK3772847 (NCT03207243) and etokimab, 
are currently being tested in phase II trials.
V. Biologicals evaluated for severe asthma currently discontinued
Despite promising findings in several experimental models of allergic inflammation, the results of 









This article is protected by copyright. All rights reserved
were negative (table S56). It appears that individual blockade of IL-4 or IL-13 alone is insufficient 
to inhibit the complex allergic inflammation. For example, blocking IL-13 does not impact 
significantly tissue eosinophilia. Other explanations could be that the biomarkers used to identify 
responders to anti-IL-13 therapy (e.g., periostin, DPP-4, peripheral eosinophil count) were not 
optimal or non T2 asthma patients were included in phase III trials. Finally, systemic 
administration could not achieve optimal lung concentrations. The preliminary efficacy of a 
nebulized inhaled anti-IL-13 mAb antigen-binding fragment in macaque model of asthma was 
recently reported (158). 
Targeting the IgE pathway via depletion of IgE-switched and memory B cells was not sufficient for 
a clinically meaningful benefit for adults with allergic asthma uncontrolled by standard therapy 
(table S56), indicating that there are major pathological mechanisms that extend beyond the new, 
local production of IgE in the lung (159). 
The results of clinical trials of biological agents targeting mediators associated with non-
eosinophilic inflammation, such as IL-17 and tumour necrosis factor (TNF)-α were disappointing 
(table S56). A better understanding of the mechanisms of non-eosinophilic inflammation in 
asthma should lead to improved therapies, with potential targeted treatment for (29,30,31).
VI. Clinical decision algorithm for the initiation and follow-up of biologicals for the 
treatment of patients with uncontrolled severe asthma
The algorithm developed by the GDG assumes that the diagnosis of severe asthma was correctly 
performed according to the current guidelines (GINA 2020, ERS/ATS), all co-morbidities and 
factors influencing asthma control were correctly addressed and patients are still symptomatic on 
high-intensity controller medication or deteriorate upon step-down (2,20,21).
The GDG developed a three-pillar decision tree aiming to help the clinician in reaching the 
decision to start on a particular biological (figure 1) based on the combination between 
phenotypic traits, biomarkers and clinically relevant asthma-related end-points (exacerbations, 
symptoms, lung function, QoL, etc.), including safety (conditional recommendation, expert opinion 
based). Cost-related and regulatory aspects should also be considered in reaching the decision 
to start with a particular biological.
The GDG recommends re-evaluation of response after 4-6 months (conditional recommendation, 
expert opinion based). Of note, in some patients, exacerbations might not decrease significantly 
in this short period of time and a composite end-point should be used to define response 
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the selected outcomes (conditional recommendation, expert opinion based). As there is no 
consensus or validated criteria to define response the GDG recommends individualised 
predefined targets established by informed shared decision focused on the patient’s goals to 
control their asthma, in alignment with the principles of personalised treatment. Cost-related, 
administration at home or in the clinic and regulatory aspects should also be considered in 
establishing the predefined goals.
For suboptimal response the GDG recommends to re-assess airway inflammation and airway 
hyperresponsiveness (conditional recommendation, expert opinion based). Induced sputum is the 
preferred option to re-assess airway inflammation (conditional recommendation, expert opinion 
based) as a non-invasive validated tool. The GDG strongly recommends joint efforts from 
academia, industry and healthcare systems to develop both educational tools and resources 
supporting a wider use of induced sputum evaluation in severe asthma. 
If airway eosinophilia is not controlled the clinician is advised to address the following 
possibilities:
1. Patient is not adherent to the background controller treatment or to the general 
management plan installed to ensure optimal asthma control. The GDG considers this as 
the first step to be considered in case of suboptimal response.  Many patients stop their 
background controller treatment following the first 3-4 administrations of the biological 
(table S2) without consulting with their HCP (162). In this case the management plan 
should be re-discussed with the patient. Adherence could be monitored more closely by 
medication refills or by using smart inhalers with dose counting. The GDG considers that 
the shared decision process at the start of the treatment and establishment of common 
goals following the administration of the biological might mitigate the non-adherence to 
the overall management plan.
2. Airway eosinophilia is not driven by the pathway targeted by the biological used (106, 
162,163). In this case consider switching to biologicals targeting a different pathway 
3. Inadequate dosing. In this case consider switching to a biological targeting the same 
pathway but with different mechanism of action or route of administration (165)
4. Development of neutralising anti-drug antibodies (ADA). Following the ABIRISK 
consortium recommendations the titre, affinity, isotype and epitope mapping are important 
steps in characterising ADA (166). In this case consider switching to biologicals targeting 
a different pathway or to a biological targeting the same pathway but with different 
mechanism of action or route of administration
5. Other immune dysfunctions such as predominant ILC2 activation, autoimmune 
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activating immune complexes are driving the treatment-resistant lung eosinophilia 
(167,168,169). As these cases are very rare referral to a specialised centre after all other 
caused were excluded is recommended.
If at re-evaluation for sub-optimal response there is no airway eosinophilia and neutrophilic 
inflammation is present the biological should be interrupted and measures addressing non-T2 
asthma such as macrolides (170), should be considered (conditional recommendation, expert 
opinion based). In cases with no airway inflammation addressing airway hyperresponsiveness 
(LABA/LAMA combinations or bifunctional drugs) (172) or airway remodelling (bronchial 
thermoplasty (172) in selected cases) is recommended (conditional recommendation, expert 
opinion based).
For the duration of a biological treatment in a patient with good response according to the 
individualised predefined targets the GDG recommends continuing treatment, pending on the 
cost-efficacy evaluation and local regulatory status, while continuously monitoring for efficacy and 
safety (conditional recommendation, expert opinion based). The rationale behind this 
recommendation is the evidence that upon interruption of the biological, as for any other 
background controller of asthma, all the beneficial effect is lost. The longer-term administration 
informs as well on the long-term safety profile and might facilitate a disease-modifying effect.
VII. Discussion
a. Relevance of the EAACI Guidelines compared to GINA and ERS/ATS 
recommendations
The EAACI Guidelines recommendations for the use of currently regulatory approved biologicals 
in uncontrolled severe asthma are formulated per product and with a careful description of the 
population where the recommendation is applicable. In comparison with the current guidelines 
(GINA 2020 and ERS/ATS) the EAACI GDG considered this approach pertinent with the 
precision medicine framework, where an exact characterisation of the target population is 
advocated. Until real world evidence accumulates the only detailed description of the phenotype 
for each biological are the inclusion/exclusion criteria for the pivotal trials that allowed the 
regulatory approval. Although not immediately very helpful for the clinician the GDG considered 
important to acknowledge in the recommendations the heterogeneity of the patients with severe 
asthma and tried to be as precise as possible in the description of the phenotype. Another key 
difference is the formulation of recommendations per product as there is no proven “class effect” 
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This aspect is evident in the case of response to biologicals from the same “class” after switching 
for lack of response. 
The National Institute for Health and Care Excellence (NICE) in the United Kingdom suggests re-
evaluating patients on mepolizumab-based therapy after 12 months to verify if the frequency of 
asthmatic exacerbations has been reduced by at least 50% (173). Similar to GINA 2019 and 
ERS/ATS guidelines the clinical decision algorithm proposed by the EAACI Guidelines proposes 
re-evaluation after 4-6 months. This arbitrary cut-off was chosen based on the high-cost of these 
drugs with the assumption that the duration is long enough to select responders from suboptimal 
response. In addition, as no validated criteria exist for defining optimal response, the EAACI 
Guidelines advocate for individual predefined targets established by informed shared decision 
focused on the patient’s goals to control their asthma (43).
b. Future perspectives: barriers and facilitators
i. Precision medicine using multiple or upstream targets
Focusing on antagonising one cytokine alone (anti IL-4, anti IL-13 interventions) were either 
unsuccessful on major clinical end-point or provided a dissociated effect (26, 63,64,65, 174), with 
impact mainly on exacerbations and less on lung function or asthma symptoms (anti-IL-5, anti IgE 
interventions). This dissociated effect seems to be less pronounced for dupilumab, which binds to 
IL-4Rα and consequently blocks both IL-4 and IL-13 signalling. These observations suggest that 
only the effective simultaneous blockade of two or more main pathogenic pathways in asthma (IL-
5, IL-4/IL-13, IgE) would be more effective in the treatment of severe T2 asthma (28). The 
combined blockade of the IL-13 and IL-33 pathways leads to a greater inhibition of T2 
inflammation over inhibition of either pathway alone (175). Similarly, co-blockade of IL-13 and IL-
25 attenuated airway hyperreactivity, eosinophil infiltration in the lung, and mucus 
hyperproduction in a mouse model of allergic asthma (176). A novel dual antagonist anti-
TSLP/IL-13 bispecific antibody has entered preclinical testing (177). 
Small molecule drug (SMD)-based therapies represent an active field in pharmaceutical research 
and development. SMDs expand biologicals' therapeutic targets by reaching the intracellular 
compartment by delivery as either an oral or topically based formulation, offering both 
convenience and lower costs (178). A randomized, double-blind, placebo-controlled, crossover 
study investigating the efficacy, safety, tolerability, and pharmacokinetics of a phosphoinositide 3 
kinase (PI3K) δ inhibitor, nemiralisib, in patients with persistent, uncontrolled asthma did not 
translate into meaningful clinical improvement in spite of local inhibition of PI3K δ. Further studies 
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bacteria or frequent exacerbators (179). Being pivotal for signalling for multiple asthma-relevant 
cytokines, including IL-4, IL-5, IL-13, and TSLP, Janus kinase (JAK)/ signal transducer and 
activator of transcription (STAT) inhibition, especially delivered through the inhaled route, might 
be a novel intervention strategy for severe asthma (180,181). 
ii. Targeted treatment of non T2 asthma
No targeted therapies exist at present for the non-T2 severe asthma. It remains to be seen if such 
an endotype really exists as many data derive from cross-sectional studies or are confounded by 
the concomitant use of high dose ICS or OCS or by the co-existence of infection (182). 
Nevertheless, the identification of a non T2 profile is essential as it excludes treatment with the 
current biologicals available for severe asthma. The NHLBI PrecISE network is currently 
exploring therapeutic approaches for non-T2 asthma.
iii. Multidimensional endotyping 
Current understanding of the heterogeneity of severe asthma requires a shift in the 
methodological approach from investigator-imposed hypothesis driven clusters to the unbiased 
approach of data-driven models leading to the discovery of new pathogenetic pathways. At 
present, large amount of multi-omics, imaging, information from medical devices, Apps and 
electronic health records data are available and require effective analytic tools. Advanced 
machine learning methods such as deep learning and platforms for cognitive computing 
represent the future toolbox for the data-driven analysis of big data (31, 44, 49, 50).
iv. The disease modifying effect
The “holy Grail” for the use of biologicals in severe asthma is to validate their disease modifying 
potential (183). If this proves to be true we might consider a future potential role for biologicals in 
mild asthma to prevent the evolution towards severe cases or for the primary prevention of 
asthma in high risk individuals. Several pathways for immune modulation in T2-driven 
inflammatory diseases are described, from trained immunity, epigenetic reprogramming, B and T 
regulatory cells, to microbiome, and novel metabolic pathways (109, 184,185,186,187,188,189). 
The induction of immune tolerance involves molecular mechanisms of anergy, deletion, 
suppression, immune privilege, and ignorance. Most of the knowledge accumulated of T2 
immune modulation followed the application of allergen immunotherapy (AIT) in asthma 
(190,191,192). Currently none of the biologicals approved for the treatment of severe asthma 
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the treatment is stopped. Data from mechanistic studies on biologicals are very scarce and 
frequently contradictory. 
v. Long term safety
In healthy individuals, eosinophils contribute to protective immune responses directed against 
parasites, viral, bacterial, and fungal pathogens, are crucial for the survival of long-lived plasma 
cells and are critical regulators of local immunity and remodelling/repair in both health and 
disease (193,194). Homeostatic eosinophils present in healthy individuals in various tissues are 
related to the control of glucose homeostasis, protection against obesity, regulation of mammary 
gland development, preparation of the uterus for pregnancy, and the maintenance of the 
intestinal homeostasis in collaboration with the local microbiota (195,196,197,198). In the lung 
homeostatic eosinophils have been shown to suppress T2-driven airway responses (199). 
Besides its role against parasites IgE can exert anti-neoplastic surveillance via mast cell and 
eosinophil-mediated cytotoxicity or by engaging and re-educating alternatively-activated 
macrophages towards pro-inflammatory phenotypes and by priming all subsets to mediate anti-
tumour functions (200,201,202). IgE deficiency was associated with a higher rate of prior 
diagnosis of malignancies compared with individuals with high or very high IgE levels (203). 
However, prospective studies are essential to better evaluate the association between IgE levels 
and risk of cancer. 
The T2 cytokines IL-4 and IL-13, which signal through IL-4Rα, trigger a specialized macrophage 
phenotype (M(IL-4)) that promotes control of helminth infection and tissue repair in the lung and 
in the liver (204,205,206). IL-4 drives the production of defence collagens, SP-A and C1q, and 
the expression of their receptor, myosin 18A (206). By controlling complement activation, IL-4 
regulates the induction of IL-6, thereby influencing a key pathway involved in regenerating liver 
cell proliferation and survival (207). 
Omalizumab and mepolizumab have evidence for long-term safety above 5 years. For all the 
other biologicals there is evidence for long-term safety up until 2 years (table S2). Thus, post-
marketing surveillance, especially collected through structured registries such as International 
Severe Asthma Registry (ISAR) or Severe Asthma Network in Italy (SANI), is of utmost 
importance (208, 209). 
vi. Efficacy versus effectiveness in a real-world setting
Several reports show that a considerable proportion of patients with severe asthma remain 
uncontrolled and are not eligible for any of the available biological treatments (201). Of note 
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or very low adherence rates for ICSs and/or ICS-LABA in the 12 months before omalizumab 
initiation compared the matched cohort of nonusers (210). In addition, there might be a selection 
bias as patients prescribed mepolizumab had a different prevalence of certain comorbidities such 
as CRSwNP, higher disease burden, higher healthcare resource utilization and costs compared 
with patients prescribed omalizumab (211,212). There is inequity in access to biologicals, as 
higher likelihood of use was related with middle age, higher income, commercial insurance, and 
access to a specialist (213). 
A validated assessment tool is needed to adequately evaluate response to biologicals in real-
world settings. The Real-life Effectiveness of Omalizumab Therapy study evaluated The 
Standardized Measure to Assess Response to Therapy (SMART), a tool designed to define 
response by physician's subjective assessment of asthma symptoms and control and objective 
assessment of 6 parameters (exacerbations, steroid bursts, emergency department visits, and 
hospitalizations; lung function; ACT score).  True responders are defined as meeting both 
subjective and objective criteria (214).
vii. Efficacy and safety in the paediatric population with severe asthma
Omalizumab has good evidence for both for the 6-11- and the 12-17-years old subgroups. Data 
on the efficacy and safety of benralizumab, dupilumab and mepolizumab in the 12-17 years old 
patients with severe asthma subgroup are limited. Reslizumab has no paediatric data reported 
(table S2). Data are frequently extrapolated from adult trials and evidence for long-term use is 
lacking (215). The development of new drugs for the treatment of paediatric severe asthma 
proves difficult as: 1) criteria to diagnose severe asthma in children are ambiguous and require 
extensive step-by-step assessment; 2) there is a limited availability of a very heterogenous 
population to enter randomised placebo-controlled trials; 3) the requirements of the Paediatric 
Investigational Plan (EMA) or Paediatric Study Plan (FDA) are quite stringent. Registries like 
"Severe Paediatric Asthma Collaborative in Europe" (SPACE), the Severe asthma registry of the 
German Asthma Net or the Children’s Health Foundation Paediatric Asthma Registry might prove 
of help. Large-scale international consortia evaluating severe paediatric asthma using unbiased 
methods such as multidimensional endotyping could help to overcome this major unmet need in 
the field of biologicals for asthma.
viii. Overall efficacy on asthma and its co-morbidities
There is high incidence of T2-driven co-morbidity in severe asthma cases such as chronic 
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anaphylaxis, allergic conjunctivitis (216). A retrospective, observational study that assessed the 
efficacy of omalizumab in patients with asthma and other concomitant allergic diseases such as 
rhinosinusitis, atopic dermatitis, and allergic broncho-pulmonary aspergillosis showed 
improvement in symptoms of these allergic diseases (217). As all regulatory approved T2 
biologicals are systemically bio available improving the overall patient wellbeing by acting on the 
non-airway targets should be further explored, both in RCTs and in real life studies. Currently 
dupilumab is approved for asthma, atopic dermatitis and chronic rhinosinusitis with nasal polyps 
and omalizumab is approved for asthma and chronic urticaria and is being assessed in allergic 
rhinitis, CRSwNP and food allergies. For the EAACI guidelines subgroup analysis for reported co-
existing co-morbidities were performed and where possible recommendations were formulated 
for the use of the biological for severe asthma and associated co-morbidities. 
ix. Impact on small airways disease
Severe asthma almost always involves small airways where inhaled drugs have difficult access 
(218,219). For benralizumab, dupilumab and mepolizumab there is evidence of improving small 
airways obstruction (77, 220, 221).
c. Additional major unmet needs and research priorities
The GDG proposed several key areas of interest both for the clinician and the basic researcher 
and from the health-care point of view (box 13). Unmet needs have been assessed from the 
perspectives of different stakeholders and in most past, converged (222).
Box 13: Gaps in evidence for the use of biologicals in severe asthma and plan to address 
Gaps in evidence Plan to address Priority 
Standardising the use of biologicals in clinical practice
1. Criteria for responders and suboptimal response  (early 
stopping rules)
2. Switching rules
3. Duration of treatment in responders (late stopping rules)
4. Long-term treatment regimen in responders: longer 
interval, down-dosing, possibility of stopping treatment 
during the summer months, switch to strategies like topical 
application, etc.
5. Identification of factors related to failure
6. Efficacy in cases of prior failure to other biologicals
7. Routine measurement of ADA
Prospective trials testing the clinical 
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Implementation of guidelines for the use of biologicals in clinical 
practice
In-depth education of HCPs on T2 
inflammation recognising the 
involvement of both the innate and 
the adaptive immune system. 
High
Long-term safety data Well-structured post-marketing 
surveillance using severe asthma 
registries
High
Assess the long-term efficacy/disease modifying effect of biologicals in 
severe  asthma (after treatment cessation) 
Identify biomarkers related to the
course of asthma (223)
Well-designed RCT and real-life 
studies focusing on long-term efficacy
Mechanistic studies at a single cell 
level 
High 
Efficacy and safety data in the paediatric population RCT and RWE trials/registries focused 
primarily on the paediatric population
High
Cost-effectiveness of biologicals in severe asthma Sectoral and generalised cost-
effectiveness analysis, including the 
real-word perspective
Long-term perspective as disease 
modifying intervention and thereby 
influence long-term cost 
High 
Identification of clinically relevant biomarkers in order to select 
responders to the current available biologicals 
Proof of concept studies evaluating 
patient selection based on biomarkers 
High 
Impact of multi- morbidities (allergic rhinitis, atopic dermatitis, 
CRSwNP, food allergy, etc) 
Studies evaluating the global effect of 
biologicals on multi- morbidities 
High 
Fair accessibility to severe asthma correct diagnosis and optimal 
targeted treatment
Reorganisation of severe asthma care
Implementation of the patients’ 
perspective from research to models 
of care
Implementation of management 
pathways/clinical decision systems
High
Comparison between biologicals Independent head-to-head 
comparison between biologicals, 
ideally with cross-over design
High 
Alignment of studies (including RWE) with guidance from regulatory 
bodies. 
Work in partnership with regulatory 
bodies to continuously review trial 
methodology and outcomes. 
Medium 
Correlation between biological and clinical response to biologicals Well-designed RCT, example for 
personalised medicine 
Medium 
The impact of age on the short and the long-term effects (efficacy and 
safety) of treatment with biologics?
Well-designed RCT, example for 
personalised medicine 
Medium 
Does 'resistance' occur as in antibiotic or anti-cancer therapy and what 
are the underlying molecular mechanisms?
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Validation of different regimens: shorter or longer intervals ('pulse-
wise') rather than as a chronic ('maintenance') therapy (e.g. to prevent 
resistance)?
RCTs and real-life studies testing 
different approaches in terms of dose, 
duration and route
Medium 
Seasonal approach with other biologicals following the model of 
omalizumab
RCTs and real-life studies Medium
VIII. Conclusion
The addition of targeted treatment for severe asthma based on phenotyping has proved of real 
value as is recommended by all contemporary guidelines on the management of severe asthma. 
This significant change in the management of severe asthma was supported by improved 
understanding of the contribution of immune-inflammatory mechanisms, followed by a relative 
fast development of biologicals and small molecules specifically targeting the innate and adaptive 
immune response. There are several critical points impacting the efficacy of this stratified 
approach, from the complexity of disease endotypes to the effectiveness in real-world settings. 
The EAACI Guidelines on the use of biologicals for uncontrolled severe asthma offers a desk 
reference tool for the healthcare providers, patients, regulators and healthcare systems based on 
a critical appraisal of the current evidence and a structured approach in formulating 
recommendations in alignment with the key principles of personalised medicine and 
implementation science.
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This algorithm is based on a precise diagnosis of severe asthma uncontrolled under high 
intensity treatment after all other measures for reaching asthma control were 
implemented, as described in the GINA 2020 and the ERS/ATS guidelines
A three-pillar decision tree supports the clinician in reaching the decision to start on a 
particular biological based on the combination between phenotypic traits, biomarkers 
and clinically relevant asthma-related end-points, including safety (conditional 
recommendation, expert opinion based). Cost-related and regulatory aspects should also 
be considered in reaching the decision to start with a particular biological.
Re-evaluation of response should be done after 4-6 months (conditional 
recommendation, expert opinion based). As there is no consensus or validated criteria to 
define response the definition of a suboptimal response relies on individualised 
predefined cut-offs of the selected outcomes established by informed shared 
decision focused on the patient’s goals to control its asthma, in alignment with the 
principles of personalised treatment (conditional recommendation, expert opinion based). 
Cost-related and regulatory aspects should also be considered in establishing the 
predefined goals.
I. For suboptimal response re-assessment of airway inflammation using induced 
sputum and airway hyperresponsiveness are recommended (conditional 
recommendation, expert opinion based). 
A. If lung eosinophilia is not controlled the clinician is advised to address the following 
possibilities:
1. Patient is not adherent to the background controller treatment or to the general 
management plan installed to ensure optimal asthma control. The asthma management 
plan should be re-discussed with the patient. 
2. Eosinophilia is not driven by the pathway targeted by the biological used. In this 
case consider switching to biologicals targeting a different pathway 
3. Inadequate dosing. In this case consider switching to a biological targeting the 









This article is protected by copyright. All rights reserved
4. Development of neutralising anti-drug antibodies (ADA). The titre, affinity, isotype 
and epitope mapping are important steps in characterising ADA. In this case consider 
switching to biologicals targeting a different pathway or to a biological targeting the same 
pathway but with different mechanism of action or route of administration
5. Other immune dysfunctions such as predominant ILC2 activation, autoimmune 
mechanisms or IL-5-anti-IL-5 complement activating immune complexes are driving the 
treatment-resistant lung eosinophilia. As these cases are very rare referral to a 
specialised centre after all other caused were excluded is recommended.
B. If at re-evaluation for suboptimal response there is no lung eosinophilia and 
neutrophilic inflammation is present the biological should be interrupted and measures 
addressing non-T2 asthma should be considered (conditional recommendation, expert 
opinion based). In case of no inflammation addressing airway hyperresponsiveness 
(LABA/LAMA combinations or bifunctional drugs) or airway remodelling (bronchial 
thermoplasty in selected cases) is recommended (conditional recommendation, expert 
opinion based).
II. In a patient with good response according to the individualised predefined targets 
treatment should be continued, pending on the cost-efficacy evaluation and local 
regulatory status, while continuously monitoring for efficacy and safety (conditional 
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Table 1: Description of the biologicals included in the EAACI Guidelines
Biological Target and mechanism of action
Benralizumab
IgG1 kappa humanised monoclonal antibody.
Binds to the α subunit of the IL-5 receptor (IL-5Rα) with inhibition of the
hetero-oligomerization of α and β subunits and thus no signal transduction
occurs. The afucosylated site of benralizumab enhances its binding to
FcγRIIIa leading to antibody-dependent cell-mediated cytotoxicity by NK cells
and macrophages. Depletes the eosinophils and reduces basophil levels.
Dupilumab
IgG4 human monoclonal antibody.
Binds to the α subunit of the IL-4 receptor (IL-4Rα) shared by IL-4 and IL-13
receptor complexes, thus simultaneously inhibiting both IL-4- and IL-13-
mediated signalling pathways. IL-4 and IL-13 are key cytokines for
orchestration of type 2 immune responses. Simultaneous blocking of Type I
receptor (IL-4Rα/γc) and Type 2 receptor (IL-4Rα/IL-13Rα) inhibit at the same
time type 2 responses depending on IL-4 and IL-4/IL-13, respectively,
in hematopoietic and non-hematopoietic cells.
Mepolizumab
IgG1 kappa humanised monoclonal antibody specific for IL-5.
Binds to a specific epitope of IL-5 and prevents it from binding to IL-5Rα.
Inhibits the maturation, activation, proliferation and recruitment of eosinophils.
Omalizumab
IgG1 kappa humanised monoclonal antibody.
Binds to free IgE and inhibits the binding of IgE to both the high- and low-
affinity IgE receptors (FcεRI and CD23, respectively). The reduction in
surface bound IgE on FcεRI-bearing cells reduces the expression of this
receptor in mast cells, basophils and dendritic cells, thus blocking the degree
of release of cytokines and mediators of the allergic response
and IgE-mediated presentation of Th2 cells. It also enhance
the production of IFN-α by pDCs, thus reducing viral-induced exacerbations.
Reslizumab
IgG4 kappa humanised monoclonal antibody.
Binds to a specific epitope IL-5 and prevents it from binding to IL-5Rα.
The in vitro affinity of reslizumab for IL-5 is higher than mepolizumab and the
capacity to suppress IL-5-dependent proliferation in vitro is also superior.
Inhibits the maturation, activation, proliferation and recruitment of eosinophils.
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Table 2_Agache et al.
Table 2: EMA recommendations for the use of biologicals in severe asthma












) Add-on maintenance treatment in adult and
adolescent patients with severe eosinophilic
asthma inadequately controlled despite high-
dose ICS corticosteroids plus LABA.
30mg SC
every 4 weeks
for the first 3 doses,
and then every
8 weeks thereafter.
Intended for long-term treatment.
The need for continued therapy
should be considered
at least on an annual basis
as determined by physician
assessment of the patient’s
disease severity and level of
control of exacerbations. Special












Adults and adolescents 12 years and older
as add-on maintenance treatment for severe
asthma with type 2 inflammation
characterised by raised blood eosinophils
(> 150) and/or raised FeNO >20),
inadequately controlled with high dose ICS
plus another maintenance treatment.
On OCS or with
co-morbid AD,
initial dose of 600 mg
followed by 300 mg
every other week SC.
For all other patients,
initial dose of 400 mg
followed by 200 mg
every other week SC.
Intended for long-term treatment.
The need for continued therapy
should be considered at least
on an annual basis based












Severe refractory eosinophilic asthma
in adults, adolescents and children
aged 6 years and older.
> 12 years old 100 mg
SC (pre-filled pen)
once every 4 weeks.
Children 6-11 years
old 40 mg SC (powder
for solution) once
every 4 weeks.
Intended for long-term treatment.
The need for continued therapy
should be considered at least
on an annual basis
as determined by physician
assessment of the patient’s
disease severity and level












>12 years old: add-on therapy to improve
asthma control in patients with severe
persistent allergic asthma who have
a positive skin test or in vitro reactivity
to a perennial aeroallergen and who have
reduced lung function (FEV1<80%) as well
as frequent daytime symptoms or night-time
awakenings, and who have had multiple
documented severe asthma exacerbations
despite daily high-dose ICS + LABA.
6-12 years old: add-on therapy to improve
asthma control in patients with severe
persistent allergic asthma who have
a positive skin test or in vitro reactivity
to a perennial aeroallergen and frequent
daytime symptoms or night-time
awakenings, and who have had multiple
documented severe asthma exacerbations
despite daily ICS+LABA.
SC every 2-4 weeks
based on total IgE
level and body weight.
Intended for long-term treatment.
Assessed for effectiveness at 16













Adult patients with severe eosinophilic
asthma inadequately controlled
despite high-dose ICS plus another
maintenance treatment.
iv per body weight
(see table)
Intended for long-term treatment.
The need for continued therapy
should be considered at least
on an annual basis as determined
by physician assessment of the
patient’s disease severity and
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Table 3: FDA recommendations for the use of biologicals in severe asthma












) Add-on maintenance treatment
of patients with severe asthma
aged 12 years and older,
and with an eosinophilic phenotype
(blood eosinophil counts greater than
or equal to 150 cells/μL).
30 mg administered SC once
every 4 weeks for the first

















) Add-on maintenance treatment
in patients with moderate-to-severe
asthma aged 12 years and older
with an eosinophilic phenotype
or with oral corticosteroid
dependent asthma.
1. An initial dose of 400 mg
followed by 200 mg given
every other week.
2. An initial dose of 600 mg







dermatitis start with an
initial dose of 600 mg




















of patients with severe asthma
aged 12 years and older,
and with an eosinophilic phenotype
(blood eosinophils of ≥ 150 cells/mcL
at screening (within 6 weeks of dosing)
or blood eosinophils of ≥ 300 cells/mcL
within 12 months of enrollment).
100 mg administered
subcutaneously




3. Herpes zoster infections
4. Abrupt discontinuation












Moderate to severe persistent asthma
in patients 6 years of age and older
with a positive skin test or in vitro
reactivity to a perennial aeroallergen and
symptoms that are inadequately controlled
with inhaled corticosteroids.
75 to 375 mg SC every
2 or 4 weeks.
Determine dose (mg)
and dosing frequency
by serum total IgE level
(IU/mL), measured before the
start of treatment, and body



















Add-on maintenance treatment of patients
with severe asthma aged 18 years and
older with an eosinophilic phenotype
(blood eosinophil count of at least
400 cells/mcL within 3 to 4 weeks
of dosing).
3 mg/kg once every 4 weeks
administered by intravenous






of OCS or ICS
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Table 4: Structured questions for the systematic reviews
“Is the treatment with biologicals (i.e., benralizumab, dupilumab, mepolizumab, omalizumab
and reslizumab) efficacious and safe for patients with uncontrolled severe eosinophilic
asthma?”
“Is treatment with benralizumab, dupilumab and omalizumab efficacious and safe for patients
with allergic asthma?”
“Is the treatment with dupilumab efficacious and safe for patients with severe asthma?”
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Decrease in ICS dose and OCS dose
Rescue medication use
Important
FeNO, sputum and blood eosinophils Low importance
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Table 6_Agache et al.
Table 6: Clinical questions not covered by the systematic reviews
1. Dose not approved by FDA/EMA
2. Route not approved by FDA/EMA
3. Biological not approved by EMA/FDA
4. Relevance of clinical trial population for real-world patients
5. Efficacy in the paediatric population, especially 6-11 years old
6. Safety long term (> 5 years)
7. Safety in the paediatric population
8. Immunogenicity
9. Best method to monitor anti-drug antibodies (ADA)




14. Defining efficacy; definition of responder, partial responder
(dissociated outcome), non-responder
15. Time to achieve efficacy
16. Treatment duration
17. Combinations between biologicals
18. Effects after administration in the emergency department
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Table 7_Agache et al.





Most individuals in this situation would want the
recommended course of action and only a small
proportion would not. Formal decision aids are not likely
to be needed to help individuals make decisions
consistent with their values and preferences.
The majority of individuals
in this situation
would want the suggested
course of action
but many would not.
For clinicians
Most individuals should receive the intervention.
Adherence to this recommendation according
to the guideline could be used as a quality criterion
or performance indicator.
Recognise that different choices
will be appropriate for individual
patients and that you must help
each patient arrive
at a management decision
consistent with his or her values
and preferences.
Decision aids may be useful
helping individuals
making decisions consistent
with their values and preferences.
For policy
makers
The recommendation can be adapted as policy
or performance measure in most situations
Policy making will require
substantial debate
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2. Eosinophilia
is not driven
by the pathway targeted





to the overall asthma
management plan





















































































for non-T2 asthma (low-dose
macrolides, dual bronchodilators,
bronchial thermoplasty, etc.)
Continue while continuously monitoring safety
Collect RWE using validated tools (registries, RELEVANT
criteria, health economics) as a basis for guidelines update
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